Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors

被引：0
|
作者：
Hui-Te Hsu
Chu-Chun Yu
Yun-Hsiang Lee
Jui-Chun Chan
Chia-Yu Chu
机构：
[1] Department of Dermatology,School of Nursing
[2] Far Eastern Memorial Hospital,Department of Nursing
[3] National Taiwan University College of Medicine,Department of Nursing
[4] National Taiwan University Hospital,Department of Dermatology
[5] Mackay Medical College,undefined
[6] National Taiwan University Hospital and National Taiwan University College of Medicine,undefined
来源：
Supportive Care in Cancer | 2022年 / 30卷
关键词：
Quality of life; Adverse events; Epidermal growth factor receptor-tyrosine kinase inhibitors; Osimertinib; Lung cancer; Paronychia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9211 / 9219
页数：8
相关论文
共 50 条
  • [1] Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors
    Hsu, Hui-Te
    Yu, Chu-Chun
    Lee, Yun-Hsiang
    Chan, Jui-Chun
    Chu, Chia-Yu
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9211 - 9219
  • [2] New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer
    Joana Espiga Macedo
    World Journal of Respirology, 2016, (02) : 57 - 62
  • [3] A review on adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in nonsmall cell lung cancer patients
    Biswas, B.
    Ghadyalpatil, N.
    Krishna, M., V
    Deshmukh, J.
    INDIAN JOURNAL OF CANCER, 2017, 54 : S55 - S64
  • [4] Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
    Hasegawa, Takaaki
    Sawa, Toshiyuki
    Futamura, Yohei
    Horiba, Akane
    Ishiguro, Takashi
    Marui, Tsutomu
    Yoshida, Tsutomu
    INTERNAL MEDICINE, 2015, 54 (16) : 1977 - 1980
  • [5] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2013, 76 (05) : 249 - 257
  • [6] Association between epidermal growth factor receptor-tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non-small cell lung cancer
    Byun, Joo-Young
    Aiyeolemi, Ayobami
    Qdaisat, Aiham
    Park, Chanhyun
    CANCER, 2024,
  • [7] Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
    De Pas, Tommaso
    Toffalorio, Francesca
    Manzotti, Michela
    Fumagalli, Caterina
    Spitaleri, Gianluca
    Catania, Chiara
    Delmonte, Angelo
    Giovannini, Monica
    Spaggiari, Lorenzo
    de Braud, Filippo
    Barberis, Massimo
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : 1895 - 1901
  • [8] Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis
    Yin, Xiaonan
    Zhao, Zhou
    Yin, Yuan
    Shen, Chaoyong
    Chen, Xin
    Cai, Zhaolun
    Wang, Jian
    Chen, Zhixin
    Yin, Yiqiong
    Zhang, Bo
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (03): : 919 - 933
  • [9] Epidermal growth factor receptor-tyrosine kinase inhibitors, which is the best choice?
    Oguri, Tetsuya
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S306 - S308
  • [10] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
12345